03 · What You Need to Know
Low Enrollment Is a Signal, Not Permission to Improvise
Start by asking where the recruitment funnel is failing
“Recruitment is failing” is too vague to guide a solution.
Break the process into stages.
Reach
Are enough potentially eligible people actually seeing the invitation?
Interest
Of those who see it, how many inquire or click through?
Screening
How many interested people meet the eligibility criteria?
Consent
How many eligible people decline after learning what participation involves?
Enrollment
How many consented participants actually begin the study?
Different failures imply different causes.
Low reach may indicate an ineffective channel. High interest but low eligibility may indicate that the target population is rarer than expected or the advertisement is reaching the wrong audience. High eligibility but low consent may indicate burdens, scheduling problems, privacy concerns, inadequate compensation, unclear information, or features of the study that people simply do not want.
You need the diagnosis before proposing the amendment.
Check whether the approved plan is actually being implemented
Before changing the protocol, determine whether the existing strategy has genuinely been tried as approved.
Were all approved sites activated?
Were advertisements posted for the intended duration?
Did gatekeepers actually distribute them?
Are recruiters using the approved script?
Are inquiries being answered promptly?
Is the recruitment link working?
Are scheduling delays causing interested participants to disappear?
Are approved reminders actually being sent?
A broken QR code does not require broader eligibility criteria. A site coordinator who forgot to send invitations does not prove the target population is impossible to recruit.
Operational failure and protocol failure are different problems.
Some improvements may already be permitted by the approved plan
Protocols differ in how specifically recruitment is approved.
One study may specify a single advertisement on a named platform. Another may approve several channels, multiple sites, reminder schedules, or alternative recruitment materials from the outset.
Researchers should review the approval letter, protocol, recruitment materials, ethics-committee procedures, and institutional requirements before assuming either that a change is prohibited or that it is automatically permitted.
The governing question is not “Does this feel minor to me?”
It is “Is this activity already within what was approved, or does the reviewing body require a modification?”
Recruitment materials are not merely marketing assets
Researchers sometimes treat posters, advertisements, social-media copy, and recruitment emails as flexible promotional materials.
FDA takes a different view for clinical investigations. It considers direct advertising to prospective participants the beginning of the informed-consent and participant-selection process and expects IRB review of recruitment methods and materials. When advertising is introduced later, FDA states that it may be treated as an amendment to the ongoing study.
That means poor response does not automatically authorize a more aggressive headline, stronger benefit claims, larger payment typography, new platform, or revised eligibility language.
Even apparently cosmetic changes can alter what potential participants understand about the study.
Changing eligibility criteria changes more than recruitment
One of the fastest ways to increase the recruitment pool is to loosen inclusion or exclusion criteria.
It can also change the study.
Expanding the age range, accepting participants without a previously required diagnosis, changing prior-exposure requirements, altering geographic restrictions, or removing exclusions may affect risk, scientific validity, participant characteristics, analysis, consent information, and the justification originally reviewed by the ethics committee.
Eligibility criteria are protocol elements, not recruitment suggestions.
If the criteria are scientifically unnecessary, that may be an excellent reason to propose an amendment. It is not a reason to ignore them while waiting for approval.
Increasing incentives may solve one problem and create another
If participants consistently say the study takes too much time for the offered compensation, increasing payment may be reasonable.
It may also require ethics review.
OHRP describes payment as generally acceptable but expects IRBs to consider whether remuneration creates undue influence. FDA similarly expects IRBs to review the amount and payment schedule in applicable clinical research.
The recruitment crisis does not change the ethical question.
“Nobody will join for $20, so we changed it to $200” may be a sensible proposal. It is still a proposal that should follow the review process applicable to the study.
Adding new recruiters can change voluntariness
A study struggling to recruit employees may decide to ask supervisors to personally encourage participation.
Enrollment might improve dramatically.
So might pressure.
Likewise, asking teachers to recruit their own students, clinicians to recruit their own patients, or service providers to recruit dependent clients can introduce authority relationships absent from the original plan.
A new recruiter is therefore not always a neutral operational change.
Before expanding recruitment through authority figures, consider how the new relationship changes participants' freedom to refuse.
Adding sites or populations can affect the whole study
A researcher unable to recruit enough participants at one university may decide to include another university.
That sounds straightforward.
The new site may have different permissions, ethics requirements, participant demographics, gatekeepers, data-protection arrangements, consent processes, languages, or institutional responsibilities.
Similarly, recruiting a new participant population may alter risk and the applicability of safeguards.
Site expansion should therefore follow the governance procedures applicable to the research rather than being treated as a larger mailing list.
More reminders are not always harmless
One reminder may be approved.
Ten reminders may not be ethically equivalent.
Increasing contact frequency can affect voluntariness, especially when reminders are personalized or sent through authority figures.
A participant who ignores one email may be expressing disinterest through silence. A researcher who repeatedly follows up may gradually make that silence harder to maintain.
Before increasing reminder frequency, check whether the approved recruitment plan specifies how many reminders may be sent and through which channels.
Do not turn ethical recruitment into persistence until resistance disappears.
Changing the advertisement may change the ethics
Recruitment teams often respond to poor performance using ordinary marketing logic:
Make the headline stronger.
Lead with payment.
Emphasize benefits.
Add urgency.
Simplify the inconvenient details.
Research recruitment cannot be optimized solely for conversion.
FDA expects recruitment advertising for clinical studies to avoid coercive presentation and promises or implications of favorable outcomes beyond the protocol and consent document. It also advises against emphasizing payment through larger or bold type.
Before rewriting an underperforming invitation, consider whether the proposed version would become more persuasive in ways that distort the participation decision.
The amendment should address the diagnosed problem
An ethics amendment is not merely paperwork standing between the researcher and a preferred recruitment tactic.
A strong amendment explains why recruitment is underperforming, what evidence supports that diagnosis, what change is proposed, and what effects the change may have on participant selection, voluntariness, risk, privacy, consent, and scientific validity.
For example:
“Recruitment is slow” is weak.
“Across eight weeks, the approved advertisement generated 420 visits to the screening page, 96 completed screeners, and only 11 eligible volunteers. Seventy-three screen failures resulted from the geographic criterion. We propose expanding recruitment to two additional approved geographic areas while retaining all other criteria and procedures.”
The second explanation gives reviewers something to evaluate.
Do not implement the amendment while waiting for approval
This is the point most likely to become inconvenient.
You submit the amendment. Recruitment deadlines are approaching. You are fairly sure the ethics committee will approve it.
Can you start using the new advertisement now?
Under HHS/FDA IRB procedures, changes in approved research generally may not be initiated without prior IRB review and approval except where necessary to eliminate apparent immediate hazards to participants.
Slow recruitment is not an apparent immediate hazard to participants.
The fact that a thesis deadline, grant milestone, or project schedule is approaching does not transform a recruitment amendment into an emergency safety measure.
The immediate-hazard exception is not a recruitment loophole
The exception permitting changes without prior approval exists so researchers can protect participants from apparent immediate hazards.
For example, an unexpected safety issue might require immediate protective action before formal review can occur.
“We need 80 more participants before December” is not that kind of hazard.
Researchers should therefore avoid invoking emergency language for schedule, budget, or sample-size problems.
Sometimes the right answer is to revise the study's ambitions
Not every recruitment problem has a clever recruitment solution.
The target population may simply be too small. The burden may be too high. The recruitment window may be unrealistic. The original feasibility assumptions may have been wrong.
Researchers may need to consider an approved change in sample size, design, timeline, sites, methods, or research question, depending on the study.
Those changes can have scientific consequences. A smaller sample may reduce statistical power or precision. Changing the design may affect comparability with the original analysis plan.
Ethics and methodology meet here: enrolling participants into a study that can no longer answer its research question can itself raise ethical concerns because participants assume burdens for diminished scientific value.
Recruitment failure is useful feasibility information
Researchers naturally experience recruitment problems as failure.
Sometimes they are evidence.
If eligible people consistently decline because participation requires six clinic visits, that tells you something about feasibility. If almost nobody meets the inclusion criteria, that tells you something about the population assumptions. If one recruitment channel reaches nobody, that tells you something about access.
The scientifically mature response is not always “recruit harder.”
Sometimes the protocol needs reconsideration.
Watch Out
Do not make a series of individually “small” unapproved recruitment adjustments until the study being conducted is materially different from the study that was reviewed. Protocol drift often arrives one reasonable shortcut at a time.
